RESPINOR is developing a novel, non-invasive, ultrasound-based medical device, DXT (Diaphragm Excursion Technology), to improve clinical decision-making in critically ill patients. DXT has the first ultrasound sensors that can stick to the skin for continuous monitoring of our main breathing muscle, the diaphragm. The diaphragm is as critical to our respiratory system as the heart is to the cardiovascular system. There are no standardized and objective technologies for continuous diaphragm monitoring available. RESPINOR’s technology is the winner of Horizon 2020 funding both in phase I and II. The company has successfully completed clinical feasibility studies in Europe for the first target segment mechanical ventilation (MV) with technical proof of principle and proof of concept confirmed. Our technology has a broad range of potential benefits and represents a technology platform for applications in critical care and other areas of respiratory medicine.